VCM
LEGN icon

Versant Capital Management’s Legend Biotech LEGN Stock Holding History

Versant Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$578 Buy
+20
New +$539 ﹤0.01% 2687

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Versant Capital Management's LEGN Position: Q2 2026 in Review

Versant Capital Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 20 shares worth $578. The stake represents ﹤0.01% of the portfolio and ranks #2687 among its holdings.

219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Versant Capital Management held 20 shares of Legend Biotech worth $578 as of Q2 2026.
  • Legend Biotech was a new Versant Capital Management position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2687 holding.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.